BioPharm International - February 2020

BioPharm-Outsourcing eBook

Issue link:

Contents of this Issue


Page 27 of 29

28 BioPharm International eBook February 2020 Biopharma Contract Market Update CMOs and CDMOs expanded their services and facilities in 2019 and early 2020. C ontract manufacturing organizations (CMOs) and contract development and manufacturing organizations (CDMOs) cont i nue to g row a nd e x pa nd to keep up with the latest advances and breakthroughs in services and technology for their clients. The following are some notable acquisitions, expansions, and industry partnerships that have occurred in recent months. ACQUISITION Catalent continued its expansion into the cell and gene t herapy development a nd ma nu fac t u r i ng services sector with an announced acquisition of MaSTherCell Global, Inc., a cell and gene therapy CDMO with facilities in Europe and the United States (1). The Feb. 3, 2020 announcement follows a May 2019 purchase of Paragon Bioservices for $1.2 billion and the acquisition of development and manufactur- ing facilities from Novamax in June 2019. "MaSTherCell extends our leadership position in the biotech industry, complements our leading gene therapy offering, and allows us to deliver compre- hensive development, manufacturing, analytical, fill/ finish, and clinical supply solutions for innovators across the large-molecule space," said John Chiminski, Catalent's chair and CEO, in the press statement. NEW FACILITIES, EXPANSIONS, UPDATES Catalent announced it completed the purchase of Bristol-Myers Squibb's biologics, sterile, and oral solid dose product manufacturing and packaging A Stockphoto - THE EDITORS OF BIOPHARM INTERNATIONAL Outsourcing Resources Operations

Articles in this issue

Links on this page

Archives of this issue

view archives of BioPharm International - February 2020 - BioPharm-Outsourcing eBook